Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Bevacizumab Combination for Advanced HCC
NCT04393220Phase 2Completed
- Sponsor
- Fuda Cancer Hospital
- Start
- May 2020
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing Bevacizumab + Nivolumab, Bevacizumab Monotherapy and Nivolumab Monotherapy (3 arms). Primary endpoints: Progression Free Survival at 1.5 years and Overall Survival at 1.5 years. Started May 2020; status: completed.
02
Drugs
nivolumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04393220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04393220.